Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1963 2
1966 1
1967 2
1968 3
1969 1
1970 3
1971 2
1972 1
1974 2
1975 1
1976 3
1977 1
1978 2
1979 5
1980 6
1981 12
1982 12
1983 9
1984 16
1985 24
1986 30
1987 20
1988 33
1989 31
1990 39
1991 35
1992 46
1993 38
1994 48
1995 53
1996 52
1997 53
1998 37
1999 54
2000 56
2001 68
2002 63
2003 54
2004 54
2005 76
2006 69
2007 86
2008 73
2009 86
2010 61
2011 54
2012 66
2013 81
2014 53
2015 63
2016 53
2017 75
2018 77
2019 80
2020 96
2021 78
2022 77
2023 74
2024 47
2025 30

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,233 results

Results by year

Filters applied: . Clear all
Page 1
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW. Xu RH, et al. Among authors: matsuoka h. Lancet Oncol. 2018 May;19(5):660-671. doi: 10.1016/S1470-2045(18)30140-2. Epub 2018 Mar 16. Lancet Oncol. 2018. PMID: 29555258 Clinical Trial.
Analysis of gut microbiome, host genetics, and plasma metabolites reveals gut microbiome-host interactions in the Japanese population.
Tomofuji Y, Kishikawa T, Sonehara K, Maeda Y, Ogawa K, Kawabata S, Oguro-Igashira E, Okuno T, Nii T, Kinoshita M, Takagaki M, Yamamoto K, Arase N, Yagita-Sakamaki M, Hosokawa A, Motooka D, Matsumoto Y, Matsuoka H, Yoshimura M, Ohshima S, Nakamura S, Fujimoto M, Inohara H, Kishima H, Mochizuki H, Takeda K, Kumanogoh A, Okada Y. Tomofuji Y, et al. Among authors: matsuoka h. Cell Rep. 2023 Nov 28;42(11):113324. doi: 10.1016/j.celrep.2023.113324. Epub 2023 Nov 6. Cell Rep. 2023. PMID: 37935197 Free article.
Postprandial microvascular dysfunction.
Matsuoka H. Matsuoka H. Circ J. 2009 Aug;73(8):1399-400. doi: 10.1253/circj.cj-09-0445. Circ J. 2009. PMID: 19628923 Free article. No abstract available.
Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma.
Kameda T, Shide K, Tahira Y, Sekine M, Sato S, Ishizaki J, Takeuchi M, Akizuki K, Kamiunten A, Shimoda H, Toyama T, Maeda K, Yamashita K, Kawano N, Kawano H, Hidaka T, Yamaguchi H, Kubuki Y, Kitanaka A, Matsuoka H, Shimoda K. Kameda T, et al. Among authors: matsuoka h. Viruses. 2022 Mar 29;14(4):710. doi: 10.3390/v14040710. Viruses. 2022. PMID: 35458440 Free PMC article.
Optimizing smartphone psychotherapy for depressive symptoms in patients with cancer: Multiphase optimization strategy using a decentralized multicenter randomized clinical trial (J-SUPPORT 2001 Study).
Akechi T, Furukawa TA, Noma H, Iwata H, Toyama T, Higaki K, Matsuoka H, Zenda S, Iwatani T, Akahane K, Inoue A, Sagara Y, Uchida M, Imai F, Momino K, Imaizumi G, Yamaguchi T, Mashiko T, Miyaji T, Horikoshi M, Sakurai N, Onishi T, Kanemitsu Y, Murata T, Wanifuchi-Endo Y, Kuroda H, Nishikawa R, Miyashita M, Abe M, Uchitomi Y; J‐SUPPORT 2001 Study group. Akechi T, et al. Among authors: matsuoka h. Psychiatry Clin Neurosci. 2024 Jun;78(6):353-361. doi: 10.1111/pcn.13657. Epub 2024 Mar 11. Psychiatry Clin Neurosci. 2024. PMID: 38468404 Free PMC article. Clinical Trial.
Utility of the refined EBMT diagnostic and severity criteria 2023 for sinusoidal obstruction syndrome/veno-occlusive disease.
Ichikawa H, Yakushijin K, Kurata K, Tsuji T, Takemoto N, Joyce M, Okazoe Y, Takahashi R, Matsumoto S, Sakai R, Kitao A, Miyata Y, Saito Y, Kawamoto S, Yamamoto K, Ito M, Murayama T, Matsuoka H, Minami H. Ichikawa H, et al. Among authors: matsuoka h. Bone Marrow Transplant. 2024 Apr;59(4):518-525. doi: 10.1038/s41409-024-02215-4. Epub 2024 Jan 29. Bone Marrow Transplant. 2024. PMID: 38287083 Free PMC article.
Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study.
Tambo Y, Sone T, Nishi K, Shibata K, Kita T, Araya T, Shirasaki H, Shimizu T, Yoneda T, Matsuoka H, Nanjo S, Koba H, Terada N, Ueda T, Nomura S, Murase Y, Yano S. Tambo Y, et al. Among authors: matsuoka h. Lung Cancer. 2025 Mar;201:108422. doi: 10.1016/j.lungcan.2025.108422. Epub 2025 Feb 4. Lung Cancer. 2025. PMID: 39952082 Free article.
Layer-Number-Independent Two-Dimensional Ferromagnetism in Cr3Te4.
Wang Y, Kajihara S, Matsuoka H, Saika BK, Yamagami K, Takeda Y, Wadati H, Ishizaka K, Iwasa Y, Nakano M. Wang Y, et al. Among authors: matsuoka h. Nano Lett. 2022 Dec 28;22(24):9964-9971. doi: 10.1021/acs.nanolett.2c03532. Epub 2022 Dec 14. Nano Lett. 2022. PMID: 36516275
Recent trends (2016-2017) in the treatment of inflammatory bowel disease.
Masaki T, Kishiki T, Kojima K, Asou N, Beniya A, Matsuoka H. Masaki T, et al. Among authors: matsuoka h. Ann Gastroenterol Surg. 2018 Jun 2;2(4):282-288. doi: 10.1002/ags3.12177. eCollection 2018 Jul. Ann Gastroenterol Surg. 2018. PMID: 30003191 Free PMC article. Review.
2,233 results